CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Aspirin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000151
NCT00000151Phase 3Completed

Early Treatment Diabetic Retinopathy Study (ETDRS)

National Eye Institute (NEI)·interventional·Posted Sep 24, 1999·Updated Sep 4, 2006

In Brief

A Phase 3 clinical trial evaluating Aspirin and Argon Laser Photocoagulation for Blindness and Diabetic Retinopathy. Completed.

Detailed Summary

To evaluate the effectiveness of both argon laser photocoagulation and aspirin therapy in delaying or preventing progression of early diabetic retinopathy to more severe stages of visual loss and blindness. To help determine the best time to initiate photocoagulation treatment in diabetic retinopathy. To monitor closely the effects of diabetes mellitus and of photocoagulation on visual function. To produce natural history data that can be used to identify risk factors and test etiologic hypotheses in diabetic retinopathy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
1979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 24, 1999
Enrollment StartDec 1, 1979
TodayJul 2, 2026
Posted 26.8 years ago

Interventions

Aspirindrug

Argon Laser Photocoagulationprocedure